MERCK & CO., INC.
Patent Owner
Stats
- 72 US PATENTS IN FORCE
- 5 US APPLICATIONS PENDING
- Mar 15, 2018 most recent publication
Details
- 72 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 51,756 Total Citation Count
- Feb 16, 1971 Earliest Filing
- 3,455 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2017/0128,599 FOLATE-CONJUGATES AND CORRESPONDING METAL-CHELATE COMPLEXES FOR USE IN DIAGNOSTIC IMAGING AND RADIOTHERAPYNov 22, 16May 11, 17[A61K, C07F, C07D, G01N, C07B]
2010/0130,453 USE OF FOLATES FOR THE PREVENTION AND TREATMENT OF VASCULAR DISEASESJan 15, 10May 27, 10[A61K, A61P]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9555038 Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseasesDec 31, 13Jan 31, 17[A61K, C07D]
9180128 Stable pharmaceutical compositions of 5,10-methylene tetrahydrofolateJun 28, 04Nov 10, 15[A61K]
8685370 Integrin targeting agents and in-vivo and in-vitro imaging methods using the sameMar 13, 09Apr 01, 14[A61K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2016/0030,573 STABLE PHARMACEUTICAL COMPOSITIONS OF 5,10-METHYLENETETRAHYDROFOLATEAbandonedOct 15, 15Feb 04, 16[A61K]
8637555 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereofExpiredOct 29, 04Jan 28, 14[A61K, C07D]
2013/0302,825 USES OF MACROPHAGE MANNOSE RECEPTOR TO SCREEN COMPOUNDS AND USES OF THESE COMPOUNDSAbandonedSep 27, 11Nov 14, 13[G01N]
2013/0266,981 EXPRESSION OF CLASS 2 MANNOSIDASE AND CLASS III MANNOSIDASE IN LOWER EUKARYOTIC CELLSAbandonedSep 21, 12Oct 10, 13[C12P]
2013/0052,670 METHOD FOR DETECTION OF AMYLOID BETA OLIGOMERS IN A FLUID SAMPLE AND USES THEREOFAbandonedJul 09, 12Feb 28, 13[G01N]
2012/0231,497 SELECTIVE ENZYMATIC HYDROLYSIS OF C-TERMINAL TERT-BUTYL ESTERS OF PEPTIDESAbandonedMay 17, 12Sep 13, 12[C12P, C07K]
2012/0213,728 GRANULOCYTE-COLONY STIMULATING FACTOR PRODUCED IN GLYCOENGINEERED PICHIA PASTORISAbandonedOct 25, 10Aug 23, 12[A61K, C12P, C12N]
8242150 Triazole derivatives for treating alzheimer'S disease and related conditionsExpiredJun 09, 08Aug 14, 12[A61K, C07D]
2012/0004,222 CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAINAbandonedAug 18, 08Jan 05, 12[A61K, C07D, A61P]
2011/0286,916 GENERATION AND CHARACTERIZATION OF ANTI-NOTCH ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC USEAbandonedNov 16, 09Nov 24, 11[A61K, C12N, G01N, A61P, C07K]
2011/0286,921 18F-LABELLED FOLATES AS PET RADIOTRACERSAbandonedOct 12, 09Nov 24, 11[A61K, C07D, G01N]
2011/0288,154 RNA Interference Mediated Inhibition of Epithelial Sodium Channel (ENaC) Gene Expression Using Short Interfering Nucleic Acid (siNA)AbandonedNov 18, 09Nov 24, 11[A61K, C07H, A61P]
2011/0171,729 Method for Producing Stable Mammalian Cell Lines Producing High Levels of Recombinant ProteinsAbandonedMay 03, 07Jul 14, 11[C12N]
2011/0003,862 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric DiseasesAbandonedFeb 15, 07Jan 06, 11[A61K, C07D, A61P]
7814721 Double fret-shaped improved sheath for laying floors and/or linings with tiles, parquet, moquette, wall-paper, panel coatings and the like, as well as their quick pulling away in case of their replacementExpiredOct 05, 04Oct 19, 10[E04D]
2010/0261,741 Quinazolinone T-Type Calcium Channel AntagonistsAbandonedJun 28, 10Oct 14, 10[A61K, C07D, A61P]
2010/0240,647 Treatment of Alzheimer's Disease and Related ConditionsAbandonedJan 23, 07Sep 23, 10[A61K, C07D, A61P]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.
